Recent research has shown that systemic administration of CPG-C, a toll-like receptor 9 agonist, combats brain metastases by activating microglia, which play a pivotal role in tumor suppression and phagocytosis upon direct tumor interaction. Here, TLR9 is linked to neoplasm.